Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...
Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback